CrystalGenomics, Inc.

KOSDAQ 083790.KQ

CrystalGenomics, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 32.96

CrystalGenomics, Inc. Price to Sales Ratio (P/S) is 32.96 on January 14, 2025, a -20.16% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

CrystalGenomics, Inc. 52-week high Price to Sales Ratio (P/S) is 62.29 on March 18, 2024, which is 88.98% above the current Price to Sales Ratio (P/S).
CrystalGenomics, Inc. 52-week low Price to Sales Ratio (P/S) is 31.91 on October 16, 2024, which is -3.19% below the current Price to Sales Ratio (P/S).
CrystalGenomics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 40.94.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

KOSDAQ: 083790.KQ

CrystalGenomics, Inc.

CEO	Dr. Joong-Myung Cho Ph.D.
IPO Date	Jan. 6, 2006
Location	South Korea
Headquarters	Tower A, Korea Bio Park
Employees	65
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials

Description

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years